Altered neurotransmission in stress-induced depressive disorders: The underlying role of the amygdala in depression.
Amygdala
Depression
GABA
Glutamate
Neuropeptide cholecystokinin (CCK)
Journal
Neuropeptides
ISSN: 1532-2785
Titre abrégé: Neuropeptides
Pays: Netherlands
ID NLM: 8103156
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
06
11
2022
revised:
30
12
2022
accepted:
18
01
2023
pubmed:
27
1
2023
medline:
11
3
2023
entrez:
26
1
2023
Statut:
ppublish
Résumé
Depression is the second leading cause of disability in the world population, for which currently available pharmacological therapies either have poor efficacy or have some adverse effects. Accumulating evidence from clinical and preclinical studies demonstrates that the amygdala is critically implicated in depressive disorders, though the underlying pathogenesis mechanism needs further investigation. In this literature review, we overviewed depression and the key role of Gamma-aminobutyric acid (GABA) and Glutamate neurotransmission in depression. Notably, we discussed a new cholecystokinin-dependent plastic changes mechanism under stress and a possible antidepressant response of cholecystokinin B receptor (CCKBR) antagonist. Moreover, we discussed the fundamental role of the amygdala in depression, to discuss and understand the pathophysiology of depression and the inclusive role of the amygdala in this devastating disorder.
Identifiants
pubmed: 36702033
pii: S0143-4179(23)00003-3
doi: 10.1016/j.npep.2023.102322
pii:
doi:
Substances chimiques
gamma-Aminobutyric Acid
56-12-2
Cholecystokinin
9011-97-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102322Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no competing interests.